Navigation Links
The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan
Date:11/14/2011

NEW YORK, Nov. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

http://www.reportlinker.com/p0365376/The-2011-Prostatic-Acid-Phosphatase-Testing-Market-US-Europe-Japan

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the PAP testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.

Contains 242 pages and 11 tables

Table of Contents

I. Introduction

II. Worldwide Market and Technology Overview

A. Prostatic Acid Phosphatase: Clinical Significance

and Laboratory Practices

B. Instrumentation Review And

Market Needs

1. Abbott AxSYM

2. Abbott IMx

3. Anagen AN2000/AuraFlex

4. Beckman Coulter Access

5. BioChem Pharma SR1

6. bioMerieux Vidas Series

7. Biotrol Systems 7000

8. J&J Diagnostics/Amersham Amerlite

9. J&J Diagnostics Vitros ECI

10. Olympus PK Series

11. Roche Cobas Core

12. Roche Elecsys

13. Roche ES 22

14. Roche ES 33

15. Roche ES 300/300 AL

16. Siemens ACS: 180

17. Siemens ACS: Centaur

18. Siemens ELISA Processor II/III

19. Siemens Immuno 1

20. Siemens/Opus/Plus/Magnum

21. Siemens Stratus

22. Tosoh AIA Series

23. Wallac/Pharmacia Delfia

C. Current and Emerging Technologies

1. Monoclonal and Polyclonal Antibodies

2. Immunoassays

a. Technological Principle

b. Radioimmunoassay (RIA)

c. Enzyme Immunoassays (EIA)

Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

Enzyme Amplification

d. Fluorescent Immunoassays

e. Luminescence

Chemiluminescence

Bioluminescence

3. Molecular Diagnostics

a. Technology Overview

b. Amplification Methods

PCR

DAP-PCR

Immuno-PCR

QC-PCR

CAR

DNA

HPA

LCR

NASBA

QBR

SDA

3 SR, and others

4. Biochips/Microarrays

5. Chromosome Analysis

a. Chronic Myelogenous Leukemia (CML)

b. Acute Myeloid Leukemia (AML)

c. Acute Lymphoblastic Leukemia (ALL)

d. Malignant Lymphomas

Lymphoid Malignancies

e. Chronic Lymphocytic Leukemia (CLL)

f. Solid Cancers

6. Microcomputers and Automation

7. Artificial Intelligence

8. Flow Cytometry

9. Biosensors

D. Competing/Complementing Technologies

1. CT

2. MRI

3. NMR

4. PET

5.Photonics Spectroscopy

E. Personal Testing

III. France: Market Size, Growth and Major Suppliers' Sales and Market Shares

IV. Germany: Test Volume and Diagnostics Sales Forecast by Market Segment

V. Italy: Test Volume and Diagnostics Sales Forecast by Market Segment

VI. Japan: Market Size, Growth and Major Suppliers' Sales and Market Shares

VII. Spain: Test Volume and Diagnostics Sales Forecast by Market Segment

VIII. U.K.: Test Volume and Diagnostics Sales Forecast by Market Segment

IX. U.S.A.: Market Size, Growth and Major Suppliers' Sales and Market Shares

X. Design Criteria for Decentralized Testing Products

XI. Alternative Market Penetration Strategies

A. Internal Development

B. Collaborative Arrangements

C. University Contracts

D. Distribution Strategies

1. Marketing Approaches

2. Product Complexity

3. Customer Preference

4. Established Suppliers

5. Emerging Suppliers

6. Major Types of Distributors

7. Market Segmentation Factor

XII. Potential Market Entry Barriers and Risks

A. Market Maturity

B. Cost Containment

C. Competition

D. Technological Edge and Limitations

E. Patent Protection

F. Regulatory Constraints

G. Decentralized Testing Market Challenges

XIII. Competitive Profiles

Abbott

AdnaGen

Ambrilia Biopharma

AMDL

Beckman Coulter

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CanAG Diagnostics

CeMines

Cepheid

Correlogic Systems

Dako

Decode

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Gen-Probe

Guided Therapeutics

Hologic

Ipsogen

J&J Diagnostics

Kreatech

Kyowa Medex

Mackay Life Sciences

Matritech

Myriad Genetics

OncoLab

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Veridex

Wako Pure Chemicals

Wallac

Zila

List of Tables

Major Companies Developing or Marketing PAP Tests

France

PAP Test Volume and Diagnostics Sales by Market Segment

France

PAP Testing Market by Major Supplier

Germany

PAP Test Volume and Diagnostics Sales by Market Segment

Italy

PAP Test Volume and Diagnostics Sales by Market Segment

Japan

PAP Test Volume and Diagnostics Sales by Market Segment

Japan

PAP Testing Market by Major Supplier

Spain

PAP Test Volume and Diagnostics Sales by Market Segment

U.K.

PAP Test Volume and Diagnostics Sales by Market Segment

U.S.A.

PAP Test Volume and Diagnostics Sales by Market Segment

U.S.A.

PAP Testing Market by Major Supplier

To order this report:

:

Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title='The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country'>The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan

Test Volume, Sales Forecasts and Supplier Shares by Country

More  Market Research Report

Check our  Real Time Industry Data

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
2. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
3. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
4. AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure
5. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
6. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
7. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
8. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
9. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
10. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
11. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):